This session will review little-known, emerging obesity pharmacotherapy and medical device pathways in Phase 2, 3 or 4. You will have the opportunity to learn both the clinical and basic science that has led to the development of these treatment approaches, as well as the next steps and challenges for bringing the product to market. Attendees can look forward to learning about potential novel targets from both human and animal data.

You won’t want to miss this one-of-a-kind preconference session free to all registered attendees to the ObesityWeek scientific sessions.

1:45pm Welcome and Introductions
Ken Fujioka, MD
1:50pm Developing a Pipeline to Address the Global Obesity Pandemic: Challenges and Opportunities
Kevin L. Grove, PhD
2:05pm Human genetics guided discovery and validation of obesity therapeutics
Nadeem Sarwar, PhD
2:10pm Brain Mechanisms Underlying Lorcaserin Appetite Suppression
Lora Heisler, PhD
2:20pm Novel Strategies for Finding and Treating Genetic Obesity
Lee M. Kaplan, MD PhD
2:35pm Advancing the Science of Gut Sensory Modulation (GSM)
Mark Tager, MD
2:50pm Targeting the Duodenal Mucosa for Metabolic Gain
David Maggs, MD
3:05pm Q&A with Speakers
Ken Fujioka, MD